A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.

Hendrik‐Tobias Arkenau, Li Yan, Alastair Greystoke et al.|Journal of Clinical Oncology|2015

Cited by 7